Latest News

Final results from the RADICALS-HD clinical trial found no evidence that the addition of hormone therapy improved how long people lived without their cancer spreading, among patients whose doctors considered them suitable for short-term, long-term or no hormone therapy.
We will present our latest prostate cancer research from the PATCH, STAMPEDE and STAMPEDE2 trials at the 2024 ESMO Congress.
As part of our '25 at 25' series, we celebrate the Unit’s training and capacity strengthening efforts over the past two decades.